Johnson & Johnson Reports Strong 2025 Earnings, Reverses $7B Talc Reserve, and Announces Orthopaedics Business Separation
JNJ sits 70% above its 52-week low of $141.5.
Summary
Johnson & Johnson reported robust financial results for fiscal year 2025, marked by a significant increase in net earnings and a major reversal of $7.0 billion from its talc litigation reserve, alongside strategic acquisitions and the planned separation of its Orthopaedics business.
Key Events · Earnings and Guidance · JNJ
-
Strong Financial Performance
Net earnings from continuing operations increased to $26.8 billion in 2025 from $14.1 billion in 2024, with diluted EPS rising to $11.03 from $5.79. Worldwide sales grew 6.0% to $94.2 billion.
-
Major Talc Reserve Reversal
The company reversed approximately $7.0 billion from its previously accrued talc litigation reserve in March 2025, following the dismissal of a bankruptcy case, reducing the total present value of the reserve to $3.4 billion.
-
Strategic Acquisitions
Completed the acquisition of Intra-Cellular Therapies for $14.5 billion in April 2025 and Halda Therapeutics for $3.05 billion in December 2025, enhancing its Innovative Medicine portfolio.
-
Orthopaedics Business Separation Planned
Announced its intention to separate the Orthopaedics business in October 2025, with a targeted completion within 18 to 24 months.
Analysis · JNJ · Life Sciences
The 10-K filing reveals a strong financial year for Johnson & Johnson, primarily driven by a substantial increase in net earnings and a significant positive development in its talc litigation. The reversal of $7.0 billion from the talc reserve substantially de-risks a major legal overhang, which is a key positive for investors. The company also continued its strategic growth through significant acquisitions in Innovative Medicine, bolstering its pipeline and market position. The planned separation of the Orthopaedics business signals a focus on streamlining operations and unlocking value. However, investors should note the considerable impact of biosimilar competition on key products like STELARA, which saw a sharp decline in sales, and the anticipated generic entry for OPSUMIT. The $0.8 billion judgment from the Auris litigation and a $1.0 billion tax re-measurement cost also represent notable financial impacts. Overall, the report presents a company executing on strategic initiatives and managing significant legal and competitive challenges, with the talc resolution being a standout positive.
At the time of this filing, JNJ was trading at $241.13 on NYSE in the Life Sciences sector, with a market capitalization of approximately $580.3B. The 52-week trading range was $141.50 to $241.26. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.